Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis

Novartis' TARGET study found that the COX-2 inhibitor Prexige has approximately one-third the rate of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet